Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
    Meeting Abstract

    Harter, P.; Trillsch, F.; Okamoto, A.; Reuss, A.; Kim, J. W.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Tredan, O.; Nyvang, G. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results
    Meeting Abstract

    Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S. N.; Martin, A. G.; Jung, K. H.; Lugowska, I. A.; Manso, L.; Manzano, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The highs and lows of serous ovarian cancer
    Review

    Grisham, R. N.; Manning-Geist, B. L.; Chui, M. H.
    Cancer (2023)

    Fulltext@MSK | Save
  • Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: Phase 1/2 trial interim results
    Journal Article

    Hassan, R.; Butler, M.; O’Cearbhaill, R. E.; Oh, D. Y.; Johnson, M.; Zikaras, K.; Smalley, M.; Ross, M.; Tanyi, J. L.; Ghafoor, A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
    Journal Article

    González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Lorusso, D.; McCormick, C. C.; Freyer, G.; Backes, F.; Heitz, F.; Redondo, A.; more...
    European Journal of Cancer (2023)

    Fulltext@MSK | Save
  • SIOG COVID-19 Working Group recommendations on COVID-19 therapeutic approaches in older adults with cancer
    Journal Article

    Russo, C.; Mislang, A. R.; Ferraioli, D.; Soto-Perez-de-Celis, E.; Colloca, G.; Williams, G. R.; O'Hanlon, S.; Cooper, L.; O'Donovan, A.; Audisio, R. A.; more...
    Journal of Geriatric Oncology (2023)

    Fulltext@MSK | Save
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
    Guidelines

    Disis, M. L.; Adams, S. F.; Bajpai, J.; Butler, M. O.; Curiel, T.; Dodt, S. A.; Doherty, L.; Emens, L. A.; Friedman, C. F.; Gatti-Mays, M.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Somatic BAP1 loss in ovarian serous borderline tumor and recurrent low-grade serous carcinoma from a germline BAP1 mutation carrier
    Correspondence

    Chui, M. H.; Grisham, R. N.
    International Journal of Gynecological Pathology (2023)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG Oncology/Gynecologic Oncology Group study 0283
    Journal Article

    O'Cearbhaill, R. E.; Miller, A.; Soslow, R. A.; Lankes, H. A.; DeLair, D.; Segura, S.; Chavan, S.; Zamarin, D.; DeBernardo, R.; Moore, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Leave it in the past - Primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study
    Journal Article

    Sia, T. Y.; Manning-Geist, B. L.; Ehmann, S.; Lavery, J. A.; Luardo, C.; Praiss, A.; Iasonos, A.; Sonoda, Y.; Grisham, R. N.; Liu, Y. L.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save